Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Molecular Devices to attend HET Instrument and Scanlab 2012

Published: Tuesday, September 11, 2012
Last Updated: Tuesday, September 11, 2012
Bookmark and Share
Amsterdam, The Netherlands. 25th – 28th September 2012 and Copenhagen, Denmark. 25th – 27th September 2012.

Molecular Devices will be showcasing their SpectraMax® Paradigm®, ImageXpress® Micro XL with MetaXpress® 5.0 and AquaMax® Washer during HET Instrument 2012, booth 1E.087, Amsterdam RAI in Amsterdam, The Netherlands, 25-28 September 2012. They will also showcase their SpectraMax® Paradigm® and AquaMax® Washer during Scanlab 2012, booth C2-017D, Bella Center in Copenhagen, Denmark, 25-27 September 2012.

The SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform is the only user upgradeable microplate reader on the market that allows for real-time system configuration by the user in less than two minutes. The TUNE Cartridge is our latest breakthrough optical technology that combines free wavelength selection with up to 10X greater sensitivity than other monochromator-based systems. TUNE lets you optimize excitation and emission wavelengths, assay at more physiologically relevant probe concentrations and find the best fit for your application, not your reader.  Although your detection needs may change, your equipment can stay the same simply by adding a new detection cartridge.

AquaMax® Microplate Washers are configurable with user interchangeable heads for both 96- and 384-well microplate washing applications, including plate or cell washing. When used for biochemical assays, the system is configured with the 96 or 384 plate wash heads to vigorously remove unbound material and reagents in microplate wells.  By thoroughly washing plates, researchers can achieve lower background in their assays. For cell-based assays, the AquaMax Washer can be configured with the 96- and 384-well cell wash heads.  Cell wash heads have angled dispensing pins to allow extremely gentle washing of weakly adherent cell types, maintaining cell integrity while ensuring thorough washing.

MetaXpress® 5.0 High Content Image Acquisition and Analysis Software has been designed to improve the ease and speed of custom image analysis using the ImageXpress® Micro and Ultra Systems. The new software enables user-created analysis to be run on MetaXpress® PowerCore™ Software, which harnesses the speed of parallel processing and instantly cuts analysis time from hours to minutes. An interactive tool incorporated into the software allows users to create custom analysis easily, without resorting to dedicated programming expertise. MetaXpress® 5.0 also features object click-to-find, allowing scientists to rapidly identify objects of interest within their images. Investigators can easily import data from 3rd party hardware, and export measurements to a variety of formats with the new MDCStore™ Xchange Service plug-in.

We will be running a series of workshops on the SpectraMax® Paradigm® at Scanlab 2012. The workshops will cover a short introduction into the system’s working principle and a live SpectraMax® Paradigm® demonstration. We will show the dynamic concentration range of the system using a common fluorescent dye. This will include reader optimization steps to achieve the best possible signal. A second test will simulate a non-homogenous growth of a cell culture in a microplate well demonstrating the WellScan feature. Availability of the workshops are September 26th at 13:00 and 15:00 and September 27th at 10:00 amd 11:30.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!